A Multi-Institution Phase I/II Trial of Triweekly Regimen with S-1 Plus Cisplatin in Patients with Advanced Non-small Cell Lung Cancer

CDDP combined with S-1 showed a satisfactory overall survival time and acceptable toxicity profile. However, the response as the primary end point did not reach the predetermined threshold level.